Arvinas (ARVN) announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20CD3 bispecific antibody, presented in a poster at the 67th American Society of Hematology Annual Meeting and Exposition, held December 6-9, 2025, in Orlando, Florida. In a humanized high-grade B-cell lymphoma cell line-derived xenograft model, the combination of ARV-393 and glofitamab resulted in significantly enhanced tumor growth inhibition and increased rates of tumor regression compared with either agent alone. These preclinical data suggest mechanistic synergies between BCL6 degradation with ARV-393 and T-cell engagement.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target raised to $15 from $14 at Stephens
- Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold Rating
- Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
- Arvinas Reports Q3 2025 Earnings and Strategic Progress
- Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges